prx-03140 prx-03140 prx-03140 is a partial agonist (18% relative to 5-ht) of the 5-ht4 receptor that was developed by epix pharmaceuticals for alzheimer's disease. prx-03140clinical dataatc codenoneidentifiers iupac name 4-hydroxy-7-isopropyl-6-oxo-n--6,7-dihydrothienopyridine-5-carboxamide cas number869493-21-0pubchem cid54677674chemspider21377738unii7qgn8qxg7icomptox dashboard (epa)dtxsid90236013 chemical and physical dataformulac19h27n3o3smolar mass377.50 g·mol−13d model (jsmol)interactive image smiles cc(c)n1c(=o)\c(=c(\o)c2ccsc12)c(=o)ncccn3ccccc3 inchi inchi=1s/c19h27n3o3s/c1-13(2)22-18(25)15(16(23)14-7-12-26-19(14)22)17(24)20-8-6-11-21-9-4-3-5-10-21/h7,12-13,23h,3-6,8-11h2,1-2h3,(h,20,24)key:schkzzsvelpjku-uhfffaoysa-n epix pharmaceuticals inc (formerly predix pharmaceuticals inc) was a pharmaceutical company based in lexington, massachusetts. in 2009, epix was in the process of asset liquidation due to insufficient funds to stay afloat. nanotherapeutics, inc. acquired the product in 2010 conducting one clinical study in ptsd patients. in 2018 the product was transferred to nanoshift, llc. nanoshift llc and nanopharmaceutics, inc. (www.nanopharmaceutics.com) continue to support clinical studies. it has been tested in six phase 1 and phase 2 clinical trials.